What baseline assessments and ongoing monitoring should be performed for a patient starting Tezspire (tezepelumab) for asthma?

Tezspire Monitoring

For patients starting Tezspire (tezepelumab), no specific baseline laboratory tests or biomarker monitoring are required, but comprehensive baseline asthma assessment with ongoing clinical monitoring is essential.

The provided evidence does not include FDA labeling or specific guidelines for Tezspire monitoring requirements. However, based on general asthma management principles and the nature of biologic therapy, here is the practical monitoring approach:

Baseline Assessment Before Starting Tezspire

Clinical Parameters:

• Classify asthma severity using symptom frequency, nighttime awakenings, SABA use, and exacerbation history 1
• Spirometry with FEV1 and FEV1/FVC ratio to establish baseline lung function 1
• Document exacerbation frequency over the prior 12 months (number requiring oral corticosteroids, ED visits, or hospitalizations)
• Assess asthma control using validated tools like ACQ-6 score 1
• Identify comorbid conditions that may complicate asthma management: sinusitis, rhinitis, GERD, OSA, obesity, stress, or depression 1
• Document current medication regimen including inhaled corticosteroid dose, LABA use, and oral corticosteroid requirements
• Assess inhaler technique and adherence 1

Biomarkers (for phenotyping, not required for Tezspire initiation):

• Blood eosinophil count (though Tezspire works across all eosinophil levels) 2, 3
• FeNO measurement (optional, as Tezspire is effective regardless of baseline FeNO) 3
• Allergy testing if not previously performed 4

Important Note: Unlike other biologics, Tezspire does not require specific biomarker thresholds for initiation, as it demonstrates efficacy across all inflammatory phenotypes 2, 3.

Ongoing Monitoring Schedule

Visit Frequency:

• Weeks 2-6 intervals when initiating therapy to assess early response and tolerability 1
• Every 1-6 months once asthma control is achieved, with interval depending on degree of control and treatment complexity 1
• Consider 3-month intervals if planning to step down other asthma medications 1

At Each Visit, Assess:

• Asthma symptom control: daytime symptoms, nighttime awakenings, activity limitation 1
• SABA use frequency (>2 days/week indicates inadequate control) 1
• Exacerbation occurrence since last visit (requiring oral corticosteroids, ED visits, or hospitalization) 1
• ACQ-6 score to quantify asthma control (target <1.5 for well-controlled asthma) 5, 6
• Medication technique and adherence to inhaled medications 1
• Adverse effects from Tezspire or other medications 7, 8
• Oral corticosteroid dose with goal of reduction or elimination 9, 6

Spirometry Timing:

• At baseline before starting Tezspire 1
• After symptoms and peak flow stabilize on treatment (typically 3-6 months) 1
• At least every 1-2 years thereafter, or more frequently if losing control 1
• During periods of progressive or prolonged loss of control 1

Response Assessment Timeline

By 3-6 Months:

• Expect reduction in exacerbations, improved lung function (FEV1 increase of ~0.11-0.24L), and improved ACQ-6 scores 7, 8, 9
• If no clear benefit observed by 4-6 weeks and technique/adherence are satisfactory, reassess diagnosis and consider alternative approaches 10

By 12 Months:

• Assess for clinical response: ≥50% reduction in exacerbations, FEV1 improvement ≥100mL or ≥5%, ACQ-6 improvement ≥0.5 5
• Evaluate for clinical remission: ACQ-6 ≤1.5, stable lung function (FEV1 >95% baseline), no exacerbations or oral corticosteroid use 5, 6
• Real-world data shows 36-55% achieve clinical remission by 1 year, with higher rates in T2-high patients 6

Key Monitoring Pitfalls to Avoid

• Don't wait for specific biomarker levels before initiating Tezspire—it works across all phenotypes 2, 3
• Don't discontinue inhaled corticosteroids when starting Tezspire; maintain controller therapy 1
• Don't ignore increasing SABA use (>2 days/week)—this signals need for treatment adjustment 1
• Don't rely solely on symptoms—use objective measures like spirometry and validated questionnaires 1
• Don't assume lack of biomarker normalization means treatment failure—clinical and biological remission may not correlate 6

Special Considerations

For patients with baseline FEV1 ≤80% predicted, expect greater lung function improvements (mean 0.19L increase) 7. In T2-low asthma (eosinophils <300 cells/μL), Tezspire still reduces exacerbations by 60-71% 2, 8, making it unique among asthma biologics.